Numis’ Stefan Hamill spoke with Mark Swindells, Chief Operating Officer of Exscientia at this year’s Numis T500 Conference.
Exscientia develops a platform and automates drug discovery, and design using artificial intelligence-based (AI) technologies. Its compounds developed by AI systems balance potency, selectivity, and pharmacokinetic criteria in order to deliver efficacy.
As at 30 June 2016, Frontier IP Group Plc have a 5% holding in Exscientia Limited.